These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36559279)

  • 1. Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients.
    Zahr N; Urien S; Llopis B; Noé G; Tissot N; Bihan K; Junot H; Marin C; Mansour B; Luyt CE; Bleibtreu A; Funck-Brentano C
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
    Kawaguchi N; Katsube T; Echols R; Wajima T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29038272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.
    Katsube T; Echols R; Wajima T
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S552-S558. PubMed ID: 31724042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series.
    Mornese Pinna S; Corcione S; De Nicolò A; Montrucchio G; Scabini S; Vita D; De Benedetto I; Lupia T; Mula J; Di Perri G; D'Avolio A; De Rosa FG
    Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects.
    Kawaguchi N; Katsube T; Echols R; Wajima T; Nicolau DP
    J Clin Pharmacol; 2022 May; 62(5):670-680. PubMed ID: 34648652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.
    Bilal M; El Tabei L; Büsker S; Krauss C; Fuhr U; Taubert M
    Clin Pharmacokinet; 2021 Dec; 60(12):1495-1508. PubMed ID: 34420182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration.
    Möhlmann JE; van Luin M; Uijtendaal EV; Zahr N; Sikma MA
    Br J Clin Pharmacol; 2023 Dec; 89(12):3753-3757. PubMed ID: 37675616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
    Kawaguchi N; Katsube T; Echols R; Wajima T
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
    Saisho Y; Katsube T; White S; Fukase H; Shimada J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 17. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.
    Wang C; Yang D; Wang Y; Ni W
    Front Pharmacol; 2022; 13():896971. PubMed ID: 35496290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.
    Sime FB; Byrne CJ; Parker S; Stuart J; Butler J; Starr T; Pandey S; Wallis SC; Lipman J; Roberts JA
    Crit Care; 2019 Jun; 23(1):205. PubMed ID: 31171022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects.
    Katsube T; Saisho Y; Shimada J; Furuie H
    J Antimicrob Chemother; 2019 Jul; 74(7):1971-1974. PubMed ID: 31220260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
    Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
    J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.